News Releases


 

Sep 19, 2017

Insmed to Present at Two September Investor Conferences

Sep 11, 2017

Insmed Announces Closing of Public Offering

Sep 6, 2017

Insmed Announces Pricing of Public Offering of Common Stock

Sep 5, 2017

Insmed Announces Proposed Public Offering of Common Stock

Sep 5, 2017

Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)

Aug 3, 2017

Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update

Jul 27, 2017

Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017

Jul 12, 2017

Insmed to Host Analyst and Investor Day on July 19, 2017

Jun 13, 2017

Insmed to Present at the JMP Securities Life Sciences Conference

Jun 8, 2017

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

1
...
NextLast